Idiopathic inflammatory myopathies. Optimum immunosuppressive treatment

BioDrugs

Volumn 7, Issue 4, 1997, Pages 262-272

  Zilko, Paul J ^a   Mastaglia, Frank L ^a   Phillips, Beverley A ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG RESPONSE; FEVER; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEADACHE; HIRSUTISM; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; LIVER TOXICITY; LUNG TOXICITY; MOUTH ULCER; MYALGIA; MYOPATHY; NEPHROTOXICITY; OSTEOPOROSIS; PLASMAPHERESIS; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; RASH; VOMITING; X IRRADIATION;

EID: 0030811913     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707040-00003     Document Type: Article

References (43)

1. Mastaglia FL, Laing NG. Investigations of muscle disease. J Neurol Neurosurg Psychiatry 1996; 60: 256-74
2. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisolone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-87
3. Benbassat J, Gefel D, Larhott K, et al. Prognostic factors in polymyositis/dermatomyositis: a computer assisted analysis of ninety two cases. Arthritis Rheum 1985; 28: 249-55
4. Fauci AS, Dale DL. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1974; 53: 240-6
5. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49: 183-5
6. Von Knebel Doeberilz M, Koch S, Droznel H, et al. Glucocorticoid hormones reduce the expression of major histocompatibility class I antigens on human epithelial cells. Eur J Immunol 1990; 20: 35-41
7. Oddis CV. Therapy for myositis. Curr Opin Rheumatol 1991; 3: 919-24
8. Henriksson KG, Sandstedt P. Polymyositis treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982; 65: 280-300
9. Rosenberg NL, Ringel SP. Adult polymyositis and dermatomyositis. In: Mastaglia FL, editor. Inflammatory diseases of muscle. Oxford: Blackwell Scientific Publications, 1988: 87-106
10. Engel WK, Borenstein A, De Vivo DC, et al. High single dose alternate-day prednisolone in treatment of dermatomyositis/ polymyositis complex. Trans Am Neurol Assoc 1972; 97: 272-5
11. Segal R, Yarom M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990: 20: 190-9
12. Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974: 81: 182-9
13. Arnett FC, Whelton JC, Zizic TM, et al. Methotrexate therapy in polymyositis. Ann Rheum Dis 1973; 32: 536-46
14. Miller LC, Sisson BA, Tucker LB, et al. Methoirexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992; 35: 1143-9
15. Bunch TW. Prednisolone and azathioprine for poiymyositis: long-term follow-up. Arthritis Rheum 1981; 24: 45-8
16. Ramirez G, Asherson RA, Khamashta MA, et al. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990; 20: 114-20
17. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheum 1994; 6: 595-601
18. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46: 1607-12
19. Heskmall J, Saunders C, Peters AM, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1: 1063-6
20. Leuck CJ, Trend PT, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54: 1007-8
21. Grau JM, Herrero C, Casademont J, et al. Cyclosporin A as first choice for dermatomyositis. J Rheumatol 1994; 21: 381-2
22. Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989; 16: 1592-6
23. Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16: 1225-8
24. Bombardieri S, Hughes GRV, Neri R, et al. Cyclophosphamide in severe polymyositis. Lancet 1989; 1: 1138-9
25. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36: 319-24
26. Kahn MF, Arlet J, Bloch-Michel H, et al. Acute leukemias after treatment using cytotoxic agents for rheumatological purpose. Nouv Presse Med 1979; 8: 1393-7
27. Lang BA, Laxen RM, Murphy G, et al. Treatment of dermatomyositis with intravenous immunoglobulin. Am J Med 1991; 91: 169-72
28. Sussman GL, Pruzanski W. Treatment of inflammatory myopathy with intravenous gammaglobulin. Curr Opin Rheum 1995; 7: 510-5
29. Cherin P, Piette JC, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-8
30. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000
31. Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immunoglobulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996; 104 Suppl. 1: 55-60
32. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 1092-7
33. Bertorini TE, Nance AM, Horner LH, et al. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 1996; 19: 388-91
34. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Arch Neurol 1981; 38: 544-52
35. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380-4
36. Engle WK, Lighter AS, Galdi AP. Polymyositis: remarkable response to total body irradiation. Lancet 1981; 1: 658
37. Morgan SH, Bernstein RM, Coppen J, et al. Total body irradiation and the course of polymyositis. Arthritis Rheum 1985; 28: 831-5
38. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomised, prospective trial of immunosuppressive therapy. Medicine 1993; 72: 225-35
39. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19: 1385-9
40. Soueidan SA, Dalakas MC. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876-9
41. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 444: 1516-8
42. Zilko PJ, Mastaglia FL, Laing B. Intravenous immunoglobulin (IVIg) in steroid resistant inflammatory myopathies. Aust NZ J Med 1993; 23: 543
43. Wallace DJ, Metzger AL, White KK. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. Arthritis Rheum 1985; 28: 590-2